Ameriflex Group Inc. Purchases Shares of 5,463 Bristol-Myers Squibb (NYSE:BMY)

Ameriflex Group Inc. purchased a new stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 5,463 shares of the biopharmaceutical company's stock, valued at approximately $322,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Pinney & Scofield Inc. bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth about $25,000. Transce3nd LLC bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth approximately $28,000. Fairway Wealth LLC purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter worth $28,000. Comprehensive Financial Planning Inc. PA bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at about $34,000. Finally, Tacita Capital Inc bought a new position in Bristol-Myers Squibb in the fourth quarter worth approximately $39,000. Institutional investors own 76.41% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on BMY shares. Wells Fargo & Company upped their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research report on Friday, February 7th. Cantor Fitzgerald reissued a "neutral" rating and set a $55.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Jefferies Financial Group cut their price target on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $55.00 price objective (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Bristol-Myers Squibb currently has an average rating of "Hold" and a consensus target price of $58.00.

Bristol-Myers Squibb Stock Up 1.8%

NYSE:BMY traded up $0.83 on Thursday, hitting $47.80. 10,490,509 shares of the company's stock traded hands, compared to its average volume of 13,129,836. The company has a market cap of $97.27 billion, a PE ratio of -10.81, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The firm has a 50-day moving average price of $50.97 and a 200-day moving average price of $55.54. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same period in the prior year, the business posted ($4.40) earnings per share. The business's quarterly revenue was down 5.6% on a year-over-year basis. Equities analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were paid a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.19%. Bristol-Myers Squibb's dividend payout ratio (DPR) is currently 92.88%.

Insider Activity

In related news, EVP Samit Hirawat purchased 4,250 shares of the stock in a transaction dated Friday, April 25th. The stock was bought at an average cost of $47.58 per share, with a total value of $202,215.00. Following the purchase, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. The trade was a 5.36% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.